8-K Announcements
6Material company update
May 28, 2026·SEC
Material company update
May 27, 2026·SEC
Material company update
May 19, 2026·SEC
Immunic, Inc.(IMUX)Earnings, Financials & Key Ratios
IMUX•NASDAQ
Price updated Jun 11, 2026
AboutImmunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.Show more
- Revenue$0
- EBITDA-$103M-5.3%
- Net Income-$97M+3.3%
- EPS (Diluted)-6.24+37.6%
- ROE-1653.15%-289.5%
IMUX Key Insights
Immunic, Inc. (IMUX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 90 (top 10%)
✗Weaknesses
- ✗Profits declining 17.2% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Shares diluted 55.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMUX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMUX Price & Volume
Immunic, Inc. (IMUX) stock price & volume — 10-year historical chart
Loading chart...
IMUX Growth Metrics
Immunic, Inc. (IMUX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-8.19%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM38.98%
Return on Capital
10 Years-284.72%
5 Years-481.76%
3 Years-748.78%
Last Year-1702.45%
IMUX Recent Earnings
Immunic, Inc. (IMUX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026EPS
$1.08
Est $0.71
-52.1%
Revenue
—
Q1 2026
Feb 26, 2026EPS
$1.20
Est $0.90
-33.3%
Revenue
—
Q4 2025
Nov 13, 2025EPS
$0.13
Est $0.18
+27.8%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.20
Est $0.18
-11.1%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $1.08vs $0.71-52.1% | — |
| Q1 2026 | Feb 26, 2026 | $1.20vs $0.90-33.3% | — |
| Q4 2025 | Nov 13, 2025 | $0.13vs $0.18+27.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.20vs $0.18-11.1% | — |
Based on last 12 quarters of dataView full earnings history →
IMUX Peer Comparison
Immunic, Inc. (IMUX) competitors in Immunology and Inflammation Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ARQT | 3.08B | 24.59 | -189.15 | 91.34% | -0.57% | -1.41% | 0.03 | |
 VNDA | 360.56M | 6.10 | -1.63 | 8.72% | -109.99% | -61.41% | 0.04 | |
 PRAX | 7.16B | 247.98 | -18.40 | -100% | -43.02% | 0.00 | ||
 ACAD | 3.66B | 21.39 | 9.34 | 11.87% | 34.3% | 35.65% | 0.04 | |
 IDYA | 2.53B | 28.84 | -22.53 | 30.24% | -62.17% | -13.96% | 0.03 | |
 TGTX | 7.36B | 48.05 | 17.35 | 87.32% | 65.95% | 87.36% | 0.40 | |
 GILD | 156.28B | 125.87 | 18.56 | 2.39% | 30.99% | 42.33% | 1.09 | |
 BIIB | 29.52B | 199.96 | 22.65 | 1.39% | 13.92% | 7.55% | 0.38 |
Compare IMUX vs Peers
Immunic, Inc. (IMUX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMUX Income Statement
Immunic, Inc. (IMUX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | -100% | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 998K | 15K | 50K | 0 | 0 | 0 | 0 | 0 | 0 | 33K |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -998K▲ 0% | -15K▲ 98.5% | -50K▼ 233.3% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -33K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | 44.61% | 98.5% | -233.33% | 100% | - | - | - | - | - | - |
Operating Expenses | 52.66M | 38.41M | 37.03M | 48.97M | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M | 109.61M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 13.31M | 13.59M | 14.52M | 10.33M | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M | 23.53M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - |
Research & Development | 39.34M | 24.82M | 22.51M | 38.64M | 61.12M | 71.25M | 83.22M | 80.05M | 81.98M | 86.08M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 28K | 0 | 0 | 17.25M | 32.97M | 0 | 0 | 0 | 0 |
Operating Income | -52.66M▲ 0% | -42.02M▲ 20.2% | -37.03M▲ 11.9% | -48.97M▼ 32.2% | -91.67M▼ 87.2% | -119.49M▼ 30.4% | -99.22M▲ 17.0% | -98.05M▲ 1.2% | -103.23M▼ 5.3% | -109.64M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | -27.6% | 20.19% | 11.88% | -32.24% | -87.18% | -30.35% | 16.96% | 1.18% | -5.28% | - |
EBITDA | -51.66M | -42.01M | -36.98M | -48.93M | -91.58M | -119.41M | -99.11M | -97.92M | -103.06M | -109.48M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | -30.92% | 18.68% | 11.97% | -32.31% | -87.16% | -30.39% | 17% | 1.2% | -5.25% | -8.56% |
D&A (Non-Cash Add-back) | 998K | 15K | 50K | 39K | 85K | 77K | 111K | 134K | 168K | 158K |
EBIT | -52.08M | -15.15M | -37.03M | -48.97M | -91.67M | -86.52M | -99.22M | -98.05M | -103.23M | -109.64M |
Net Interest Income | 0 | 0 | 0 | 58K | 66K | 0 | 3.08M | 3.39M | 1.04M | 1.62M |
Interest Income | 650K | 521K | 107K | 58K | 66K | 1.04M | 3.08M | 3.39M | 1.04M | 1.62M |
Interest Expense | 0 | 0 | 107K | 0 | 0 | 1.04M | 0 | 0 | 0 | 0 |
Other Income/Expense | 577K | 455K | 2.1M | 4.95M | -1.28M | -919K | 5.61M | -2.46M | 6.06M | 5.35M |
Pretax Income | -52.08M▲ 0% | -41.48M▲ 20.4% | -34.93M▲ 15.8% | -44.02M▼ 26.0% | -92.94M▼ 111.2% | -120.41M▼ 29.5% | -93.61M▲ 22.3% | -100.51M▼ 7.4% | -97.17M▲ 3.3% | -104.29M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 549K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | -1.32% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -52.08M▲ 0% | -41.48M▲ 20.4% | -34.83M▲ 16.0% | -44.02M▼ 26.4% | -92.94M▼ 111.2% | -120.41M▼ 29.5% | -93.61M▲ 22.3% | -100.51M▼ 7.4% | -97.17M▲ 3.3% | -104.29M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - | - |
Net Income Growth % | -27.12% | 20.36% | 16.03% | -26.39% | -111.16% | -29.55% | 22.25% | -7.37% | 3.32% | -8.19% |
Net Income (Continuing) | -52.08M | -11.54M | -34.93M | -44.02M | -92.94M | -120.41M | -93.61M | -100.51M | -97.17M | -104.29M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -522.60▲ 0% | -391.60▲ 25.1% | -45.10▲ 88.5% | -28.10▲ 37.7% | -39.20▼ 39.5% | -37.80▲ 3.6% | -21.10▲ 44.2% | -10.00▲ 52.6% | -6.24▲ 37.6% | -3.46▲ 0% |
EPS Growth % | -0.1% | 25.07% | 88.48% | 37.69% | -39.5% | 3.57% | 44.18% | 52.61% | 37.6% | 38.98% |
EPS (Basic) | -522.60 | -391.60 | -45.10 | -28.10 | -39.20 | -37.80 | -21.10 | -10.00 | -6.24 | - |
Diluted Shares Outstanding | 99.65K | 105.92K | 772.23K | 1.57M | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M | 30.14M |
Basic Shares Outstanding | 99.65K | 105.92K | 772.23K | 1.57M | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M | 30.14M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
IMUX Balance Sheet
Immunic, Inc. (IMUX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 58.12M | 14.23M | 32.23M | 133.75M | 104.99M | 125.86M | 52.53M | 39.33M | 22.87M | 188.76M |
Cash & Short-Term Investments | 56.9M | 13.32M | 29.37M | 127.45M | 86.86M | 116.37M | 46.67M | 35.67M | 15.48M | 186.63M |
Cash Only | 56.9M | 13.32M | 29.37M | 127.45M | 86.86M | 106.75M | 46.67M | 35.67M | 15.48M | 186.63M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 9.63M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 408K | 295K | 2.15M | 296K | 703K | 684K | 4.12M | 354K |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - |
Inventory | 0 | -191K | -408K | 0 | 0 | 5.61M | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 1.22M | 0 | 1.55M | 1.35M | 1.12M | 3.59M | 2.84M | 1.11M | 3.26M | 1.06M |
Total Non-Current Assets | 2.26M | 746K | 33.73M | 34.12M | 34.11M | 1.89M | 1.76M | 1.54M | 1.18M | 983K |
Property, Plant & Equipment | 2.15M | 709K | 713K | 1.1M | 1.1M | 1.85M | 1.76M | 1.54M | 1.18M | 983K |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 32.97M | 32.97M | 32.97M | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 108K | 37K | 42K | 42K | 42K | 43K | 0 | 0 | 0 | 0 |
Total Assets | 60.38M▲ 0% | 14.98M▼ 75.2% | 65.95M▲ 340.3% | 167.86M▲ 154.5% | 139.1M▼ 17.1% | 127.75M▼ 8.2% | 54.3M▼ 57.5% | 40.87M▼ 24.7% | 24.05M▼ 41.1% | 189.74M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | -5.69% | -75.2% | 340.35% | 154.51% | -17.13% | -8.16% | -57.5% | -24.74% | -41.15% | 717.62% |
Total Current Liabilities | 10.28M | 2.51M | 7.07M | 8.4M | 11.4M | 13.08M | 24.73M | 22.18M | 30.62M | 38.36M |
Accounts Payable | 1.05M | 268K | 2.42M | 3.7M | 3.5M | 4.28M | 5.1M | 7.85M | 10.14M | 11.01M |
Days Payables Outstanding | 383.65 | 6.52K | 17.69K | - | - | - | - | - | - | 102.2K |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 470K | 275K |
Deferred Revenue (Current) | 0 | 0 | 1.01M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5.64M | 564K | 343K | 82K | 851K | 7.33M | 17.48M | 676K | 20.01M | 23.49M |
Current Ratio | 5.65x | 5.67x | 4.56x | 15.93x | 9.21x | 9.62x | 2.12x | 1.77x | 0.75x | 4.92x |
Quick Ratio | 5.65x | 5.75x | 4.62x | 15.93x | 9.21x | 9.20x | 2.12x | 1.77x | 0.75x | 4.92x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 59K | 41K | 520K | 679K | 584K | 992K | 639K | 264K | 107K | 146K |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 107K | 0 |
Capital Lease Obligations | 0 | 0 | 520K | 679K | 584K | 992K | 639K | 264K | 107K | 584K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 59K | 41K | 0 | 0 | 0 | 0 | 0 | 0 | -107K | 0 |
Total Liabilities | 10.34M | 2.55M | 7.59M | 9.08M | 11.98M | 14.07M | 25.37M | 22.44M | 30.73M | 38.51M |
Total Debt | 0 | 37.19M | 520K | 976K | 992K | 1.56M | 1.33M | 1M | 684K | 421K |
Net Debt | -56.9M | 23.87M | -28.85M | -126.48M | -85.87M | -105.18M | -45.34M | -34.66M | -14.8M | -186.21M |
Debt / Equity | - | 2.99x | 0.01x | 0.01x | 0.01x | 0.01x | 0.05x | 0.05x | - | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.70x |
Interest Coverage | - | - | -346.09x | - | - | -83.11x | - | - | - | - |
Total Equity | 50.04M▲ 0% | 12.43M▼ 75.2% | 58.36M▲ 369.6% | 158.78M▲ 172.1% | 127.11M▼ 19.9% | 113.68M▼ 10.6% | 28.93M▼ 74.6% | 18.43M▼ 36.3% | -6.67M▼ 136.2% | 151.23M▲ 0% |
Equity Growth % | -14.38% | -75.17% | 369.65% | 172.06% | -19.95% | -10.57% | -74.55% | -36.3% | -136.21% | 2703.07% |
Book Value per Share | 502.21 | 117.32 | 75.58 | 101.37 | 53.74 | 35.73 | 6.53 | 1.84 | -0.43 | 5.02 |
Total Shareholders' Equity | 50.04M | 12.43M | 58.36M | 158.78M | 127.11M | 113.68M | 28.93M | 18.43M | -6.67M | 151.23M |
Common Stock | 4K | 4K | 1K | 2K | 3K | 4K | 4K | 8K | 9K | 11K |
Retained Earnings | -295.95M | -337.43M | -59.91M | -103.93M | -196.87M | -317.28M | -410.89M | -511.4M | -608.57M | -641.16M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 78K | 80K | -1.37M | -4.11M | -252K | 3.04M | 3.76M | 4.21M | 2.65M | 3.06M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMUX Cash Flow Statement
Immunic, Inc. (IMUX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -40.4M | -43.16M | -28.55M | -46.12M | -83.23M | -65.14M | -70.83M | -84.77M | -85.81M | -81.33M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | -12.92% | -6.85% | 33.87% | -61.58% | -80.45% | 21.73% | -8.73% | -19.68% | -1.23% | -4.72% |
Net Income | -52.08M | -41.48M | -34.93M | -44.02M | -92.94M | -120.41M | -93.61M | -100.51M | -97.17M | -104.29M |
Depreciation & Amortization | 998K | 727K | 50K | 39K | 85K | 77K | 111K | 134K | 168K | 158K |
Stock-Based Compensation | 5.48M | 3.74M | 6.51M | 2.75M | 5.95M | 7.93M | 7.1M | 8.53M | 8.86M | 6.82M |
Deferred Taxes | 0 | 1.22M | -355K | 0 | 4.33M | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 255K | 234K | 1.54M | -2.53M | 8.63M | 37.73M | 523K | 6.52M | 497K | 5.06M |
Working Capital Changes | 4.95M | -7.61M | -1.36M | -2.37M | -9.28M | 9.53M | 15.05M | 564K | 1.84M | 10.92M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 287K | -770K | -462K | 1M | 176K | 799K | 817K | 3.15M | 1.24M | 4.41M |
Cash from Investing | -678K | -415K | 10.54M | -146K | -67K | -9.74M | 9.46M | -264K | -161K | -116K |
Capital Expenditures | -685K | -597K | -55K | -146K | -67K | -112K | -334K | -264K | -161K | -116K |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - | - |
Acquisitions | 7K | 0 | 10.67M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 7K | 182K | -75K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 37.98M | 4K | 34.9M | 144.43M | 42.84M | 95.76M | 1.03M | 74.54M | 65.58M | 254.22M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 74.27M | 0 | 0 |
Equity Issued (Net) | 38M | 0 | 35.16M | 144.43M | 42.75M | 95.57M | 853K | 191K | 65.58M | 254.22M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 123K |
Other Financing | -14K | 4K | -270K | 0 | 92K | 187K | 180K | 77K | 0 | 1 |
Net Change in Cash | -3.09M▲ 0% | -43.58M▼ 1310.3% | 16.3M▲ 137.4% | 98.08M▲ 501.8% | -40.59M▼ 141.4% | 19.88M▲ 149.0% | -60.07M▼ 402.1% | -11.01M▲ 81.7% | -20.18M▼ 83.4% | 172.32M▲ 0% |
Free Cash Flow | -41.08M▲ 0% | -43.76M▼ 6.5% | -28.6M▲ 34.6% | -46.27M▼ 61.8% | -83.3M▼ 80.0% | -65.26M▲ 21.7% | -71.16M▼ 9.1% | -85.03M▼ 19.5% | -85.97M▼ 1.1% | -81.45M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - | - |
FCF Growth % | -13.08% | -6.52% | 34.65% | -61.78% | -80.03% | 21.66% | -9.05% | -19.49% | -1.1% | 1.7% |
FCF per Share | -412.27 | -413.15 | -37.04 | -29.54 | -35.22 | -20.51 | -16.06 | -8.49 | -5.52 | -2.70 |
FCF Conversion (FCF/Net Income) | 0.78x | 1.04x | 0.82x | 1.05x | 0.90x | 0.54x | 0.76x | 0.84x | 0.88x | 0.78x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMUX Key Ratios
Immunic, Inc. (IMUX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -96.01% | -132.78% | -98.39% | -40.54% | -65.02% | -100.01% | -131.28% | -424.44% | -1653.15% | -220.75% |
| Return on Invested Capital (ROIC) | - | -214.13% | -84.41% | -118.82% | -186.94% | -360.29% | - | - | - | 324.46% |
| Debt / Equity | - | 2.99x | 0.01x | 0.01x | 0.01x | 0.01x | 0.05x | 0.05x | - | 0.00x |
| Interest Coverage | - | - | -346.09x | - | - | -83.11x | - | - | - | - |
| FCF Conversion | 0.78x | 1.04x | 0.82x | 1.05x | 0.90x | 0.54x | 0.76x | 0.84x | 0.88x | 0.78x |
| Revenue Growth | -100% | - | - | - | - | - | - | - | - | - |
Related:IMUX Dividend History·IMUX Revenue History·IMUX Price History·IMUX P/E History·IMUX Financial Ratios·IMUX Institutional Holders
IMUX SEC Filings & Documents
Immunic, Inc. (IMUX) SEC filings — annual & quarterly reports (10-K, 10-Q)
IMUX Frequently Asked Questions
Immunic, Inc. (IMUX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immunic, Inc. (IMUX) grew revenue by 0.0% over the past year. Growth has been modest.
Immunic, Inc. (IMUX) reported a net loss of $104.3M for fiscal year 2025.
Dividend & Returns
Immunic, Inc. (IMUX) has a return on equity (ROE) of -1653.1%. Negative ROE indicates the company is unprofitable.
Immunic, Inc. (IMUX) had negative free cash flow of $81.4M in fiscal year 2025, likely due to heavy capital investments.